Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Huperzine A in preparing medicaments

A technology of huperzine A and medicine, which is applied in the application field of huperzine A in pharmaceuticals, and achieves the effects of strong pharmacological effect, lowering eye pressure effect and good effect

Inactive Publication Date: 2010-08-11
SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But there is no report about the application of huperzine A in ophthalmology

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Huperzine A in preparing medicaments
  • Application of Huperzine A in preparing medicaments
  • Application of Huperzine A in preparing medicaments

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Embodiment one: the influence of huperzine A on the pupil diameter of rabbits

[0023] 1 Experimental materials

[0024] 1.1 Main Drugs and Reagents

[0025] Huperzine A (Institute of Materia Medica, Chinese Academy of Sciences, Shanghai).

[0026] 1.2 Test animals

[0027] New Zealand white rabbits, weighing 2.2-2.8kg, male and female, provided by the Experimental Animal Center of Shanghai Jiao Tong University School of Medicine, license number SYXK 2003-0026.

[0028] 2 Experimental method:

[0029] 2.1 Determination of the pupil

[0030] The rabbits were fixed in a rabbit box, and the pupil diameter of the rabbits was measured with a pupil ruler (Castroviejo caliper) under natural light.

[0031] 2.2 Administration method

[0032] 30 healthy white rabbits without eye diseases were selected and randomly divided into 3 groups (ten rabbits with 20 eyes in each group). Normal saline group: instill 50 μl of normal saline in each eye; huperzine A eye drop group: ins...

Embodiment 2

[0037] Example 2: Effect of huperzine A on intraocular pressure (IOP) in rabbits with high intraocular pressure induced by water load

[0038] 1 test animal

[0039] New Zealand white rabbits, weighing 2.2-2.8kg, male and female, provided by the Experimental Animal Center of Shanghai Jiao Tong University School of Medicine, license number SYXK 2003-0026.

[0040] 2 Experimental method:

[0041] 2.1 Tonometry

[0042] Fix the rabbit in a rabbit box, anesthetize the surface of the eyeball with 0.1% tetracaine, measure the intraocular pressure with a tonometer, repeat the measurement three times, take the average value, and record the intraocular pressure curve.

[0043] 2.2 Establishment of ocular hypertension model

[0044] water load induced ocular hypertension

[0045] Select healthy white rabbits without eye diseases, and inject 3% pentobarbital sodium (1 mL / kg) into each rabbit from the ear vein for general anesthesia. Both eyes were instilled with 1% tetracaine for lo...

Embodiment 3

[0052] Example 3: Huperzine A protects retinal ganglion cells (RGC-5) in vitro

[0053] 1 Experimental materials

[0054] 1.1 Cell lines

[0055] RGC-5 retinal ganglion cell line was purchased from ATCC.

[0056] 1.2 Experimental drugs and reagents

[0057] Huperzine A (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) was dissolved in DMSO to make a stock solution, stored at -20°C, and diluted to the required concentration with culture medium before use.

[0058] Glutamic acid (Glu) was purchased from Sigma, dissolved in culture medium to make a stock solution, stored at -20°C, and diluted to the desired concentration with culture medium before use.

[0059] 2 Experimental methods

[0060] Take the RGC-5 cells that grew stably and were cultured for 3-10 passages after recovery, digested with 0.25% trypsin and made cell suspension, and used 3×10 3 Inoculate in a 96-well plate, 100 μl per well. When the cells grew to 70%-80% confluence, the cells were div...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Weightaaaaaaaaaa
Login to View More

Abstract

The invention relates to application of Huperzine A in preparing medicaments, namely the application of the Huperzine A in preparing medicaments for preventing and treating glaucoma, increase of intraocular pressure and eye problems concomitant with retinal ganglion cell injury. The invention has the advantages that: 1, the new medical treatment application of the Huperzine A is developed, and a new application field is exploited; 2, the Huperzine A is safe and non-toxic, and has strong pharmacological effects, and good medicinal prospect of the Huperzine A is predicted; and 3, a great deal of cell and animal experimental study proves that the medicament Huperzine A has good effects of protecting retinal ganglion cell and reducing the intraocular pressure by oral administration and local eye dropping, and can be used for preventing and treating the glaucoma, the increase of intraocular pressure and the eye problems concomitant with retinal ganglion cell injury.

Description

【Technical field】 [0001] The invention relates to a new application of huperzine A, in particular to an application in the field of pharmacy. 【Background technique】 [0002] Glaucoma is one of the most common clinical eye diseases, mainly manifested as increased intraocular pressure leading to fundus optic nerve head collapse, narrowed field of vision, decreased vision, severe cases may be blind, and once blind, will permanently lose vision. Its incidence rate accounts for about 1% of the whole population, and the incidence rate of people over 40 years old accounts for about 2.5%, which is extremely harmful. [0003] Treatment of glaucoma has long been limited to the treatment of its main risk factor - ocular hypertension. After the intraocular pressure is controlled by drugs and / or surgery, the visual function impairment of most patients has been effectively curbed, but there are still a considerable number of patients, especially those with advanced glaucoma, whose visual...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4748A61P27/02A61P27/06
Inventor 陈红专冯雪梅崔永耀周薇朱亮容征星
Owner SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com